[서울경제TV=김혜영기자]3bix, a company specializing in bio big data platforms, and Seoul National University School of Dentistry Professor Seung-Hyun Han’s research team announced on the 9th that they published a paper on the inhibition of the growth of methicillin-resistant Staphylococcus aureus in Frontiers in Microbiology (IF: 6.064).
3bix and the research team intensively analyzed the growth inhibitory factors of methicillin-resistant Staphylococcus aureus through Next Generation Sequencing (NGS) and transcriptome analysis.
Microorganisms living in the human intestine decompose dietary fiber to produce short chain fatty acids, which are an energy source for intestinal mucosal epithelial cells and play a role in maintaining health through antibacterial action and immune regulation. Propionate, one of the short fatty acids, can suppress MRSA, and it was confirmed that it shows a calming effect that prevents bacteria from multiplying by targeting genes of major metabolic pathways, the company explained.
3bix CEO Joon-Hyung Park said, “Existing antibiotic treatments have low tissue absorption, slow bactericidal efficacy, and are difficult to control antibiotic-resistant bacteria such as MRSA, which has limitations in treating Staphylococcus aureus infections.” By changing the metabolic pathway of MRSA, it was confirmed that it can be used as a new concept bacteriostatic agent that is biocompatible and less likely to cause resistance for the prevention and treatment of MRSA infectious diseases.”
On the other hand, Staphylococcus aureus (S. aureus) is a causative agent of various diseases such as pneumonia, gastroenteritis, endocarditis, and septic shock. Among them, methicillin-resistant Staphylococcus aureus (MRSA) is a representative antibiotic-resistant Staphylococcus aureus. Infectious diseases caused by this bacterium show high morbidity and mortality worldwide, and the company explained that it is gradually increasing. /hyk@seadaily.com
< 저작권자 ⓒ 서울경제, 무단 전재 및 재배포 금지 >
